drugset

drugset / Trial / NCT02705469

A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02705469 ↗

Phase 1 Completed 44 enrolled Zenith Epigenetics

NaSingle-groupOpen-labelTreatment

Summary

This is an open label, Phase 1, dose escalation and dose confirmation study of ZEN003694 in patients with mCRPC.

Timeline

Start: 2016-05
Primary completion: 2017-10
Completion: 2017-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ZEN-3694	Small molecule	—	Oral

Indications